FDA Advisory Panel Convenes to Review Moderna mRNA Flu Vaccine Candidate
What happened
A U.S. Food and Drug Administration advisory committee is scheduled to deliberate on Moderna's investigational mRNA-based influenza vaccine. The panel review represents a formal regulatory checkpoint that precedes any potential FDA approval decision. Moderna has been expanding its mRNA platform beyond COVID-19 into seasonal vaccines, with the flu shot candidate representing one of the company's most closely watched pipeline programs. No vote outcome or approval timeline has been confirmed ahead of the meeting.
The QL Read
MRNA carries a composite signal of 56/100 (bullish-leaning) with shares down 0.25% on the day. Against a mildly constructive tape — 51.7% of issues advancing — the binary regulatory outcome from this panel sits as the cleanest near-term catalyst to watch before the signal resolves in either direction.